Remedium Bio, a Boston, MA-based biotechnology company, raised $2.3M in Expanded Seed funding.
The round was led by Sherwood Ventures with participation from, LongevityTech.Fund, Primo Medical Group, Angel Star Ventures, Apis Health Angels, MicroVentures, and Guindy Alumni Angels.
The company intends to use the funds to study its lead product, a single-injection gene therapy potentially capable of reversing cartilage loss, in a collaboration with Tufts University School of Medicine scientists researching rheumatic disorders.
Led by CEO Frank Luppino, Remedium Bio is a preclinical-stage biotechnology company developing novel gene therapies for a broad range of highly debilitating diseases. The company’s R&D approach focuses on modularly combining proven technologies to treat well-characterized disease pathology streamlining elements of the product development process. Remedium’s pipeline includes therapeutic indications in Osteoarthritis, Diabetes, Stroke, and other large unmet clinical needs.
The company’s advisory board includes Dr. Timothy McAlindon, MD, MPH, Chief of the Division of Rheumatology at Tufts Medical Center, Professor at Tufts University School of Medicine; Dr. Anastassios Pittas, MD, MS, Chief of the Division of Endocrinology, Diabetes, and Metabolism and Co-Director of the Diabetes and Lipid Center at Tufts Medical Center, Professor at Tufts University School of Medicine; Dr. Jeff Ellsworth, PhD, the pioneer of rhFGF18 technology and CSO of Recardia Therapeutics; Dr. Li Zeng PhD, MA, MS, BA Associate Professor Immunology at Tufts University School of Medicine; and Dr. Kai Zou PhD, Assistant Professor, Department of Exercise and Health Sciences, at the University of Massachusetts, Boston.
FinSMEs
16/08/2022